BPC-157 + TB-500

The BPC-157 + TB-500 Blend is a combination research product pairing two peptides frequently studied together in the tissue-repair and regeneration literature: BPC-157, a synthetic pentadecapeptide derived from a gastric protein, and TB-500, supplied here as full-length thymosin β4. The two are combined in a single product because their reported mechanisms in preclinical models are distinct and complementary — BPC-157 is associated with angiogenic and growth-factor-pathway effects, while thymosin β4 is a well-characterized actin-sequestering protein central to cytoskeletal remodeling. This page summarizes the verified chemistry of each component and the published research context. The blend is supplied strictly as a research-use product for in vitro and laboratory investigation.

BPC-157 is a 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, catalogued under CAS number 137525-51-0, with a molecular formula of C₆₂H₈₈N₁₆O₂₂ and a molecular weight of approximately 1419.55 g/mol. It is a partial sequence derived from a protein found in human gastric juice.

TB-500, as supplied in this blend, is full-length thymosin β4 — a naturally occurring 43-amino-acid peptide catalogued under CAS number 77591-33-4, with a molecular formula of C₂₁₂H₃₅₀N₅₆O₇₈S and a molecular weight of approximately 4963.4 g/mol (PubChem CID 16132341). A point of frequent confusion in this space is worth stating plainly: the designation “TB-500” was historically applied to the shorter N-terminal-acetylated actin-binding fragment (Ac-LKKTETQ, residues 17–23, approximately 878 g/mol), but most material sold under the TB-500 name is in fact the full-length 43-residue protein. The component in this blend is the full-length form, as documented on the batch-specific Certificate of Analysis.

Neither component is approved by the FDA, EMA, or any other regulatory authority for any indication. As of 2026, TB-500 has been reclassified by the FDA as a 503A Category 2 bulk drug substance and is under review by the agency’s Pharmacy Compounding Advisory Committee; researchers should be aware of the evolving regulatory status of both compounds.

Important note on the evidence base: The published literature for both peptides consists predominantly of in vitro and rodent studies; much of the BPC-157 work originates from a small number of research groups, and most thymosin β4 clinical work used the full-length protein in formulations distinct from injected research material. No combination product of BPC-157 and TB-500 has been evaluated in controlled human clinical trials. Researchers should weight the evidence accordingly and consult the primary literature in the References section.

Mechanism of Action

The two components are studied for distinct molecular mechanisms. The pathways below are drawn from preclinical work on each peptide individually; the combination itself has not been mechanistically characterized in peer-reviewed studies.

BPC-157: angiogenic and growth-factor pathways

BPC-157 has been studied for effects on blood-vessel formation and tissue-repair signaling in rodent models. Reported mechanisms include upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) signaling and modulation of the nitric oxide system, associated in the literature with effects on endothelial cell behavior and wound-healing endpoints, with much of the published work concerning gastrointestinal and musculotendinous tissue [1].

Thymosin β4 (TB-500): actin sequestration

Thymosin β4 is the primary intracellular G-actin-sequestering protein in many cell types, binding monomeric actin in a roughly 1:1 interaction and maintaining a reservoir of unpolymerized actin available for rapid filament assembly. This actin-regulatory role underlies its association with cell migration and cytoskeletal remodeling, processes relevant to tissue-repair research [2]. The actin-binding activity is concentrated in the LKKTETQ motif within the full-length sequence.

Proposed complementarity

The rationale for combining the two is that they engage non-overlapping pathways — angiogenic and growth-factor signaling for BPC-157, cytoskeletal and cell-migration regulation for thymosin β4 — both of which appear in tissue-repair research. This complementarity is a design rationale rather than an established synergistic effect; no controlled study has demonstrated that the combination outperforms either component alone.

None of the mechanisms summarized here have been verified for the combination in adequately powered human clinical trials.

Forms and Use in the Research Literature

The information below reflects how each compound appears in the published preclinical literature. It is reported strictly for research-reference purposes and does not constitute administration recommendations of any kind.

Research models. BPC-157 has been studied in rodent models of gastrointestinal, tendon, ligament, and muscle injury, typically administered at microgram-per-kilogram amounts. Thymosin β4 has been investigated in dermal wound-healing, corneal-repair, and post-ischemic cardiac models, including the full-length protein in some clinical formulations distinct from research material. No published model has evaluated the two as a fixed combination.

Capsule format. This product is supplied by Captide Labs in capsule form, consistent with the brand’s capsule-first catalog. Researchers evaluating format effects should note that the published literature for both peptides predominantly used parenteral administration in animal models, and oral or encapsulated delivery represents a distinct research variable.

Stability and storage. Both peptides are supplied as lyophilized material and are typically stored frozen, protected from light, with reconstituted solutions kept refrigerated and used promptly. Full-length thymosin β4, as a larger protein, is handled under the same general peptide-stability practices. Each lot supplied by Captide Labs is accompanied by a batch-specific Certificate of Analysis documenting the identity and purity of each component by HPLC, including the molecular weight that distinguishes full-length thymosin β4 from the shorter fragment.

Adverse-event profile. No human clinical-trial adverse-event database exists for the BPC-157 + TB-500 combination. Safety of the combination in humans has not been established, and the regulatory status of both components is in flux as described above.

References

1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. doi:10.1152/japplphysiol.00945.2010 · PubMed: 21030672
2. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. doi:10.1016/j.molmed.2005.07.004 · PubMed: 16099219
3. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144–2151. doi:10.1096/fj.09-142307 · PubMed: 20179146